The global dupuytren’s disease market size is expected to reach USD 5.87 billion by 2030, registering a CAGR of 4.55% from 2023 to 2030, according to a new report by Grand View Research, Inc. Dupuytren’s disease is a debilitating condition characterized by the abnormal thickening and shortening of palm tissue, leading to the formation of claw-like finger deformities. This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively. The industry presents lucrative prospects for stakeholders, such as pharmaceutical companies, medical device manufacturers, and healthcare providers to develop innovative therapies and interventions. As the prevalence of the condition continues to rise, there is an escalating demand for effective treatments that can improve symptoms and enhance patients' quality of life.
Consequently, intensified research and development efforts are anticipated in the near future, leading to advancements in treatment options and potential breakthroughs in managing Dupuytren's disease. In a recent study, adalimumab emerged as a potentially cost-effective treatment choice during the early stages of Dupuytren’s disease. The research findings suggest that this medication holds promise in effectively managing the condition while providing value for the investment. These results underscore the potential advantages of adalimumab as a practical and economically viable treatment option specifically for individuals in the early stages of Dupuytren’s disease. The growing awareness and understanding of the disease among healthcare professionals and patients, along with advancements in medical research and diagnostics, are driving the market expansion.
Improved detection rates and timely intervention have increased the demand for effective treatments. Endo Pharmaceuticals’ “Watching Education Unfold” campaign, featuring real patients, aims to raise awareness about Dupuytren’s contracture and educate the public and healthcare community about the condition and available treatment options. This initiative is expected to contribute to heightened awareness, early diagnosis, and improved management of contractures. In addition, significant advancements in medical technology and therapeutic approaches, such as injectable collagenase and minimally invasive surgical techniques, have played a crucial role in driving the market forward. Injectable collagenase treatment like Xiaflex has gained approval for Dupuytren's contracture in multiple countries, offering a less invasive alternative to traditional surgical procedures and leading to improved patient outcomes and shorter recovery times. These advancements in medical technology and therapeutics are significant contributors to the overall growth of the market.
Request a free sample copy or view report summary: Dupuytren's Disease Market Report
The type II disease segment dominated the market in 2022 due to its higher prevalence, more severe symptoms, and greater demand for treatment options
In addition, advancements in medical technology have focused on addressing challenges specific to type II Dupuytren's disease, leading to a wider range of effective treatments available for patients
By type, the treatment segment held a dominant revenue share in 2022 due to the increasing demand for effective treatment options to alleviate symptoms and improve the quality of life for individuals
The hospitals end-use segment held the largest market share in 2022 due to advanced infrastructure, specialized care, and referral networks
Europe established a strong regional position in the market in 2022. This can be attributed to factors, such as advanced healthcare infrastructure, increasing prevalence of the disease, and presence of key players driving innovation and access to treatment options in the region
Grand View Research has segmented dupuytren’s disease market report based on disease type, type, end-use, and region:
Dupuytren’s Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
Type I
Type II
Type III
Dupuytren’s Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
Diagnosis
Physical Examination
X-ray
Treatment
Surgery
Radiation Therapy
Needle Aponeurotomy
Steroid Shot
Enzyme Injection
Occupational Therapy
Others
Dupuytren’s Disease End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Clinics
Academic & Research Institute
Others
Dupuytren’s Disease Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Dupuytren’s Disease Market
Bayer AG
Novartis AG
Pfizer Inc
Nantong Jinghua Pharmaceutical Co, Ltd.
Actiza Pharmaceutical Pvt. Ltd.
Endo International plc
Bristol-Meyers Squibb Company
Spear Pharmaceuticals
GSK plc
AstraZeneca
Hikma Pharmaceuticals PLC
LEO Pharma A/S
Fresenius Kabi AG
"The quality of research they have done for us has been excellent..."